Galatek is a Singapore-headquartered automation and AI company building software and instruments for two highly regulated domains: life sciences smart labs and advanced semiconductor manufacturing. The company was founded in 2022 and positions itself as a vertically integrated provider that combines hardware, deep-learning models, and lab informatics in a single stack.
On the life sciences side, Galatek co-develops smart-lab platforms for diagnostics, next-generation sequencing, organoid culture, drug development, and synthetic biology. Its Abio platform unifies electronic lab notebook (ELN), laboratory information management (LIMS), and scientific data management (SDMS) capabilities with automation control, turning experimental data into structured, analyzable records. Academic partners include the National University of Singapore, alongside undisclosed pharma collaborators.
For semiconductor manufacturing, Galatek builds fully automated overlay measurement systems, deep-learning automatic optical inspection (AOI) tools, and precision wafer dicing equipment used in advanced packaging lines. The systems target the inspection and back-end packaging steps that have become bottlenecks as chip geometries shrink and chiplet designs proliferate.
The company closed a $30 million Series A on 19 December 2025. Investors were not publicly disclosed. Proceeds are earmarked for product development, expansion of delivery centers in Malaysia and the United States, and growth of local teams across Europe, North America, and Southeast Asia under what Galatek calls a 'Global Supply Chain + Localized Service' model.
Galatek's differentiator is its dual focus: most lab-automation vendors do not sell semiconductor equipment, and most semiconductor inspection vendors do not sell lab software. By straddling both, the company is betting on shared underlying capabilities in precision motion, computer vision, and AI-driven decision support.